Sepracor have settled a patent dispute with Breath Ltd allowing Breath to launch generic versions of Xopenex under terms of an exclusive license commencing on August 20, 2012.
Filed under: gpcr | Tagged: agonist, Beta 2 adrenoceptor, gpcr, levalbuterol, Sepracor, Xopenex
Name (required)
E-mail (will not be published) (required)
Website
Notify me of follow-up comments via email.
